Bristol’s Abatacept Shows Elevated Infection Risk In Phase III Safety Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A higher incidence of serious infections was seen with Bristol-Myers Squibb's rheumatoid arthritis biologic abatacept in a yearlong, Phase III safety study